Informed Surgery

New research, guidelines and FDA decisions, each with a note on what it might change in a conversation with your surgeon, how certain it is, and links to the original sources.

How we choose news. Nothing here is sponsored. Mentioning a product isn't an endorsement, and an FDA clearance means a device was found substantially equivalent to existing ones, not proven better. Updated November 2026.

Research

Five-year Evolut Low Risk results for valve-only procedures

A 2026 analysis of the Evolut Low Risk trial found death or disabling stroke at five years was similar after TAVR and surgery in people having only the valve replaced (15.5% versus 14.6%). New pacemakers were more common after TAVR (27.3% versus 8.9%).

What this could change in a conversation with your surgeon: For lower-risk patients, TAVR and surgery look similar at five years, but pacemaker risk is a real tradeoff to discuss.

Sources: Ann Thorac Surg (DOI)

See news across every procedure on the Informed Surgery news page.